Acrivon Presents ACR-2316 Phase 1/2 Data: Confirmed CR in Lung Cancer, No DLTs at Selected Doses
ACRV sits 18% above its 52-week low of $0.971 on elevated volume (4.7× avg).
Summary
Acrivon disclosed first Phase 1/2 data for ACR-2316 showing a confirmed complete response in squamous NSCLC on study over 65 weeks and no dose-limiting toxicities at the 120 mg and 160 mg doses now advancing into randomized expansion.
Key Events · Product Development and Regulatory · ACRV
-
ACR-2316 Phase 1/2 Data Presented
Dose-escalation results in 33 patients across two intermittent once-daily regimens; 120 mg and 160 mg (3 days on / 4 days off) selected for randomized dose expansion.
-
Confirmed Responses in Hard-to-Treat Tumors
One confirmed CR in squamous NSCLC on study more than 65 weeks, a confirmed PR of -41% in endometrial cancer, and an unconfirmed PR of -69% in SCLC; 5 of 7 lung cancer patients derived clinical benefit.
-
Clean Safety at Selected Doses
No Grade 4 treatment-related events and no DLTs at 120 mg or 160 mg; all DLTs were neutropenia at doses above 160 mg, with no febrile neutropenia and no Grade 5 events.
-
Expansion Phase Ongoing
The trial (NCT06667141) continues enrolling in the randomized dose-expansion phase in AP3-predicted tumor types.
Analysis · ACRV · Life Sciences
First-in-human proof of concept is now in hand for Acrivon's lead wholly-owned asset, the oral WEE1/PKMYT1 inhibitor ACR-2316. The data include a confirmed complete response in squamous NSCLC lasting more than 65 weeks, a confirmed PR in endometrial cancer, and an unconfirmed deep response in SCLC, all in heavily pretreated patients (median 3 prior lines). Equally important, the 120 mg and 160 mg doses chosen for randomized expansion produced no Grade 4 treatment-related events and no dose-limiting toxicities; the toxicity that capped dosing was transient, asymptomatic neutropenia at higher doses. That combination of durable single-agent activity and a clean safety window at the selected doses underpins the ongoing dose-expansion phase. Against the going-concern doubt disclosed in the November 16 10-Q, clinical validation of the pipeline is the main lever for financing the company beyond its stated runway.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.3M. The 52-week trading range was $0.97 to $3.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.